Ethyl trans-4-oxo-2-butenoate CAS 2960-66-9
Ethyl trans-4-oxo-2-butenoate is an intermediate of Minodronic Acid.
Indications of Minodronic acid hydrate: Osteoporosis (Minodronate intermediate, the product is used in the treatment of osteoporosis)
Osteoporosis is a systemic system in which bone microstructure is damaged, bone mineral composition and bone matrix are continuously reduced, bone is thinned, bone trabeculae are reduced, bone fragility is increased and the risk of fracture is increased Disorders of bone metabolism. Generally divided into two categories, namely primary osteoporosis and secondary osteoporosis.
Statistics abroad show that about 200 million people worldwide suffer from osteoporosis, of which more than 75 million are in the United States, Western Europe, and Japan alone. Osteoporosis is recognized as the second-biggest health killer after cardiovascular disease.
Osteoporosis, which has long been considered a disease endemic to the elderly, actually existed in childhood. In particular, it is important to emphasize that there is currently no safe and effective cure in medicine to help loose bones return to their original state.Therefore, positive identification and early prevention are particularly important.